000177194 001__ 177194
000177194 005__ 20240229133732.0
000177194 0247_ $$2doi$$a10.3390/cells10102670
000177194 0247_ $$2pmid$$apmid:34685650
000177194 0247_ $$2pmc$$apmc:PMC8534413
000177194 037__ $$aDKFZ-2021-02328
000177194 041__ $$aEnglish
000177194 082__ $$a570
000177194 1001_ $$00000-0001-8001-8793$$aHolowatyj, Andreana N$$b0
000177194 245__ $$aThe Use of Human Serum Samples to Study Malignant Transformation: A Pilot Study.
000177194 260__ $$aBasel$$bMDPI$$c2021
000177194 3367_ $$2DRIVER$$aarticle
000177194 3367_ $$2DataCite$$aOutput Types/Journal article
000177194 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1636011884_8518
000177194 3367_ $$2BibTeX$$aARTICLE
000177194 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177194 3367_ $$00$$2EndNote$$aJournal Article
000177194 520__ $$aObesity and excess adiposity account for approximately 20% of all cancer cases; however, biomarkers of risk remain to be elucidated. While fibroblast growth factor-2 (FGF2) is emerging as an attractive candidate biomarker for visceral adipose tissue mass, the role of circulating FGF2 in malignant transformation remains unknown. Moreover, functional assays for biomarker discovery are limited. We sought to determine if human serum could stimulate the 3D growth of a non-tumorigenic cell line. This type of anchorage-independent 3D growth in soft agar is a surrogate marker for acquired tumorigenicity of cell lines. We found that human serum from cancer-free men and women has the potential to stimulate growth in soft agar of non-tumorigenic epithelial JB6 P+ cells. We examined circulating levels of FGF2 in humans in malignant transformation in vitro in a pilot study of n = 33 men and women. Serum FGF2 levels were not associated with colony formation in epithelial cells (r = 0.05, p = 0.80); however, a fibroblast growth factor receptor-1 (FGFR1) selective inhibitor significantly blocked serum-stimulated transformation, suggesting that FGF2 activation of FGFR1 may be necessary, but not sufficient for the transforming effects of human serum. This pilot study indicates that the FGF2/FGFR1 axis plays a role in JB6 P+ malignant transformation and describes an assay to determine critical serum factors that have the potential to promote tumorigenesis.
000177194 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000177194 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177194 650_7 $$2Other$$aFGF2
000177194 650_7 $$2Other$$abody fatness
000177194 650_7 $$2Other$$abody mass index
000177194 650_7 $$2Other$$aobesity
000177194 650_7 $$2Other$$aoverweight
000177194 7001_ $$aGigic, Biljana$$b1
000177194 7001_ $$aWarby, Christy A$$b2
000177194 7001_ $$aOse, Jennifer$$b3
000177194 7001_ $$aLin, Tengda$$b4
000177194 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b5$$udkfz
000177194 7001_ $$00000-0001-7641-059X$$aUlrich, Cornelia M$$b6
000177194 7001_ $$aBernard, Jamie J$$b7
000177194 773__ $$0PERI:(DE-600)2661518-6$$a10.3390/cells10102670$$gVol. 10, no. 10, p. 2670 -$$n10$$p2670$$tCells$$v10$$x2073-4409$$y2021
000177194 909CO $$ooai:inrepo02.dkfz.de:177194$$pVDB
000177194 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000177194 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000177194 9141_ $$y2021
000177194 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCELLS-BASEL : 2019$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-04
000177194 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000177194 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000177194 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x0
000177194 980__ $$ajournal
000177194 980__ $$aVDB
000177194 980__ $$aI:(DE-He78)C120-20160331
000177194 980__ $$aUNRESTRICTED